Financial Performance - Reported revenues of $6.5 million in Q1 2024, representing a 116% increase compared to Q1 2023[7] - Gross margin improved to 85% in Q1 2024, up from 78% in Q1 2023, due to increased factory volumes and operational efficiency[9] - Operating losses were $11.7 million in Q1 2024, compared to $10.1 million in Q1 2023, driven by increased investments in sales, marketing, and R&D[10] - Net losses available to common stockholders were $13.2 million in Q1 2024, compared to $8.3 million in Q1 2023[11] - Full-year sales growth is expected to exceed 50%[7] Financing and Cash Position - Secured up to $50 million in debt financing with OrbiMed to support growth initiatives for the TriNav® Infusion System[4] - Cash and cash equivalents were $3.97 million as of March 31, 2024, down from $11.78 million at the end of 2023[21] - The company expects sufficient cash runway to fund operations through the end of 2025, assuming revenue targets are met[5] Corporate Governance - The company appointed Liselotte Hyveled to its Board of Directors, bringing over two decades of experience in pharmaceutical innovation[6] Shareholder Information - The weighted average common shares outstanding increased to 23,323,045 in Q1 2024 from 16,166,581 in Q1 2023[12]
TriSalus Life Sciences(TLSI) - 2024 Q1 - Quarterly Results